Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Renalytix PLC - London-based kidney health-focused diagnostics company - In the financial year to June 30, pretax loss narrows to $46.2 million from $49.6 million a year prior. Revenue grows 13% to $3.4 million from $3.0 million. Says that during financial 2023, over 5,000 KidneyIntelX tests were performed, up 55% annually. ‘We expect a meaningful increase in total tests during the remainder of fiscal 2024, building on quarterly test volumes of about 1,200 during fiscal 2023 and through first quarter of 2024. More than half of these during the first quarter of 2024 thus far are revenue generating, with a set of the Mount Sinai clinical trial tests no longer billable following last spring’s transition to full commercial payment at the hospital system,’ the company says.
Current stock price: 66.50 pence, down 14% on Thursday
12-month change: up 13%
Copyright 2023 Alliance News Ltd. All Rights Reserved.